Triple Point.

# Triple Point Venture VCT plc

## Product Overview

September 2026

We believe the UK is the best place in Europe to start and grow a business, making it the natural home of venture capital. The Triple Point Venture VCT comes with attractive tax incentives, but more importantly, it gives you access to a portfolio of over 60 ambitious early-stage companies.

## Performance

Total NAV return (NAV + dividends paid)




| Period | Jul 21 to Jul 22 | Jul 22 to Jul 23 | Jul 23 to Jul 24 | Jul 24 to Jul 25 | Jul 25 to Jul 26 |
|---|---|---|---|---|---|
| Discrete performance (NAV + dividends) | 8.89% | -7.00% | -1.12% | 1.41% | 2.70% |
| Dividends paid (pence per share) | 0p | 3p | 4p | 4p | 4p |

The above table shows the total return for the Triple Point Venture VCT per year, comprising the Net Asset Value (NAV) and dividends paid to date. The chart shows the VCT's performance on a quarterly basis over the last five years. The cumulative total return over the five years (Jul 2021 to Jul 2026) is 4.28%.

[1] Provided shares are held for a minimum of five years.

[2] Source: Beauhurst 2025

### Tax benefits of a VCT in the 2026/27 tax year

- Up to 20% upfront income tax relief[1]
- Tax-free dividends
- Tax-free growth

**A ready-built and diverse portfolio:**
The VCT features early-stage companies operating across 20 different sectors. This means investors get instant access to a diversified portfolio of exciting companies of different sizes and stages of maturity.

**B2B company focus:**
We aim to maximise potential returns by investing in business-to-business (B2B) companies over companies directly targeting consumers (B2C). This is because B2B businesses become acquisition targets at around double the rate of B2C.[2]

**Dividend target of up to 5% of the NAV per share:**
The VCT has an annual dividend target of up to 5% of the NAV per share while also targeting long-term capital growth. Since launch in 2018, the VCT has paid 21p per share in tax-free dividends.

**Important Information: This document is an advertisement for the purposes of the FCA's Prospectus Rules: Admission to Trading on a Regulated Market sourcebook (PRM) and is not a prospectus. A prospectus in respect of the Offer has been published and is available on our website. Investors should read the prospectus before making any investment decision. Approval of the prospectus by the FCA should not be understood as an endorsement of the shares offered.**

The Triple Point Venture VCT invests in smaller companies, which can involve a higher degree of risk than investing in companies listed on an exchange. Investors' capital is at risk and there is no guarantee that target returns will be achieved. Past performance and forecasts are not a reliable indicator of future performance. Tax treatment depends on the individual circumstances of each client and is subject to change. Tax reliefs depend on the VCT maintaining its qualifying status. Dividends are not guaranteed.

Call: 020 7201 8990 Email: contact@triplepoint.co.uk Visit: triplepoint.co.uk



## VCT investment illustration: Company spotlight

Paloma Health

### Team
Healthcare entrepreneurs Mark Jenkins and Darshak Shah have deep clinical, operational, and commercial expertise. Mark co-founded the digital health platform Oviva, while Darshak founded leading NHS ophthalmology provider Newmedica, which was acquired by Specsavers in 2020.

### Product
Paloma's 'Clinical OS' platform is driving clinical and operational efficiency in the critically underfunded areas of autism and ADHD (Attention Deficit Hyperactivity Disorder). By automating key workflows, the platform helps clinicians to focus on delivering care while improving the speed, quality, and scalability of services.

### Market fit
The UK's overburdened specialist care market means families often wait months or years for assessments and treatment in areas like autism, ADHD and paediatric mental health. Paloma is well-positioned to bridge this gap with a tech-enabled model that improves efficiency and access for patients.

### Investment
We led Paloma's first funding round in May 2024, and after seeing strong early progress we followed up with a further investment in May 2025. We were drawn to the founders' exceptional track records and their vision for delivering high quality specialist private care that reduced NHS waiting lists.

## Investment details

**Minimum investment:** £5,000

**Maximum investment:** There is no maximum investment, but the maximum investment on which VCT tax reliefs are currently available is £200,000 invested in a single tax year.

**Dividend policy:** Targeting regular dividends of up to 5% of NAV per VCT share annually, while also achieving long-term capital growth in the net asset value. There is also a dividend reinvestment scheme available to VCT investors.

**Offer closing date:** 30 July 2027 unless fully subscribed at an earlier date. The deadline for receiving applications and cleared funds for final allotment in the 2026/27 tax year is 11am on 5 April 2027.

## Investment fees and charges

**Initial charge:** 2.5%

**Annual management charge:** 2.0%

**Performance fee:** 20% of realised profits on exits over investment cost plus a 3% annual compound threshold. A high water mark will apply to subsequent performance fees to ensure that any prior performance hurdle is exceeded.

Triple Point can facilitate adviser and distributor initial and ongoing fees.

**Loyalty share discount:** Existing investors in the Venture VCT are eligible for a 1% loyalty discount on the initial fee for all applications.

**Early bird discount:** 1% discount is available for all completed applications received before 31 December 2026, or on the first £5m raised, whichever is reached first.

For full details on the fees and charges for the Triple Point Venture VCT, please see the Prospectus and Key Information Document (KID), both of which are available to download at triplepoint.co.uk.

For information on our Sustainability Disclosure Requirements (SDR) and the investment labels applied to the Triple Point Venture VCT, visit triplepoint.co.uk/sustainability-resources/

For further information about the Triple Point Venture VCT, please call 020 7201 8990 or email contact@triplepoint.co.uk

This document has been approved by Triple Point Administration LLP, which is authorised and regulated by the Financial Conduct Authority.
Triple Point is the trading name for the Triple Point Group, which includes the following companies and associated entities: Triple Point Investment Management LLP registered in England & Wales no. OC321250, authorised and regulated by the Financial Conduct Authority no. 456597, Triple Point Administration LLP registered in England & Wales no. OC391352 and authorised and regulated by the Financial Conduct Authority no. 618187, and TP Nominees Limited registered in England & Wales no. 07839571, all of 1 King William Street, London, EC4N 7AF, UK.